KYMR Kymera Therapeutics, Inc.
KYMR Kymera Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 2 scans as of 2026-08-17 2 bull converging
POC $85.74 · VWAP $79.61 · +52.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
3 watchlists
KYMR Price Structure
Loading timeframes…
Peers
Every watchlist KYMR belongs to, members best 30-day change first — KYMR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
@monster-discoveries
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Against street estimates
How KYMR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about KYMR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Kymera Therapeutics (KYMR) Stock Price, News & Analysis
- Kymera Therapeutics (KYMR) Earnings Date and Reports 2026
- Kymera Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
- Get the latest Kymera Therapeutics, Inc. (KYMR) stock news and headlines
- Kymera Q4 2025 results, $1.6B cash runway to 2029 | KYMR Stock News
KYMR research tape
34 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to KYMR.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries